BenzingaSeptember 1, 2026 at 8:11 AM NYLast Month
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273
Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $275 to $273.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
